Key Finding
SMYA decoction significantly reduced myocardial cell apoptosis and improved cardiac function after ischemia-reperfusion injury through dose-dependent activation of the PI3K-AKT signaling pathway.
Researchers investigated how Simiao Yong'an (SMYA) decoction, a traditional Chinese herbal formula, protects the heart after heart attacks. Heart attacks occur when blood flow to the heart is blocked, and even after blood flow is restored, additional damage can happen during what's called reperfusion injury. In traditional Chinese medicine theory, heart attacks are linked to qi stagnation and blood stasis, conditions that SMYA is traditionally used to address.
The study combined computer modeling with laboratory experiments using rats. Scientists first identified 25 active compounds in SMYA and analyzed how they might work in the body. They then tested the formula on rats with induced heart attacks, giving them SMYA treatment for 7 days and measuring heart function at different time points.
The results showed that SMYA significantly improved heart function and reduced markers of heart damage in the blood. The herbal formula worked by activating a specific cellular pathway called PI3K-AKT, which helps prevent heart muscle cells from dying. The protective effects were both dose-dependent (higher doses worked better) and time-dependent (effectiveness varied at different stages after the heart attack). The research confirmed that SMYA reduces cell death in heart tissue and improves the heart's pumping ability.
For patients interested in Chinese herbal medicine for cardiovascular health, this research provides scientific evidence supporting SMYA's traditional use for heart conditions. However, this was an animal study, and more human research is needed. Always consult with a licensed acupuncturist or qualified traditional Chinese medicine practitioner before using herbal formulas for heart conditions.
This study employed systematic pharmacology and experimental validation to elucidate SMYA decoction's cardioprotective mechanisms in myocardial ischemia-reperfusion injury. UPLC-Q-TOF/MS identified 25 bioactive compounds, with network pharmacology revealing 161 key targets and 167 KEGG pathways, prominently featuring the PI3K-AKT pathway. In a rat cardiac I/R model (45-minute ischemia, 24-hour reperfusion), 7-day SMYA administration significantly reduced serum CK-MB and LDH levels while improving LVEF and FS. Western blot analysis confirmed dose-dependent activation of PI3K-AKT signaling and modulation of apoptosis-related proteins (BAX, Bcl-2, caspase-3). Molecular docking validated binding affinity between SMYA components and AKT/BCL-2. The study demonstrates SMYA's anti-apoptotic effects through PI3K-AKT pathway activation, providing mechanistic evidence for its traditional application in qi stagnation and blood stasis patterns underlying acute myocardial infarction. Clinical integration should consider dose-response relationships and timing of intervention during acute phases.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 QSYQ formula improved heart failure outcomes in mice by restoring myocardial energy metabolism through AMPK pathway activation, increasing ATP production while reducing oxidative stress and improving cardiac function.
📌 Chinese herbal medicine use in chronic kidney disease patients was associated with a 23-31% reduction in risk of major adverse cardiac events and all-cause mortality over a 17-year follow-up period.
📌 Six food and medicine homology plants demonstrate multi-target therapeutic mechanisms in coronary heart disease through immunomodulation, particularly affecting CD4+ memory activated T cells and naïve B cells, with four hub genes showing validated causal associations with CHD.